Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

An innovative approach to characterize clinical ADME and pharmacokinetics of the inhaled drug nemiralisib using an intravenous microtracer combined with an inhaled dose, and an oral radiolabel dose in healthy male subjects.

Harrell AW, Wilson R, Lun Man Y, Riddell K, Jarvis E, Young G, Chambers R, Crossman L, Georgiou A, Pereira A, Kenworthy D, Beaumont C, Marotti M, Wilkes D, Hessel EM, Fahy WA.

Drug Metab Dispos. 2019 Oct 24. pii: dmd.119.088344. doi: 10.1124/dmd.119.088344. [Epub ahead of print]

2.

Airway host-microbiome interactions in chronic obstructive pulmonary disease.

Wang Z, Maschera B, Lea S, Kolsum U, Michalovich D, Van Horn S, Traini C, Brown JR, Hessel EM, Singh D.

Respir Res. 2019 Jun 6;20(1):113. doi: 10.1186/s12931-019-1085-z.

3.

Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals.

Wilson R, Templeton A, Leemereise C, Eames R, Banham-Hall E, Hessel EM, Cahn A.

Clin Ther. 2019 Jun;41(6):1214-1220. doi: 10.1016/j.clinthera.2019.04.008. Epub 2019 May 7.

PMID:
31076203
4.

Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase δ Inhibitor.

Begg M, Edwards CD, Hamblin JN, Pefani E, Wilson R, Gilbert J, Vitulli G, Mallett D, Morrell J, Hingle MI, Uddin S, Ehtesham F, Marotti M, Harrell A, Newman CF, Fernando D, Clark J, Cahn A, Hessel EM.

J Pharmacol Exp Ther. 2019 Jun;369(3):443-453. doi: 10.1124/jpet.119.257311. Epub 2019 Apr 2.

PMID:
30940692
5.

Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.

Begg M, Wilson R, Hamblin JN, Montembault M, Green J, Deans A, Amour A, Worsley S, Fantom K, Cui Y, Dear G, Ahmad S, Kielkowska A, Clark J, Boyce M, Cahn A, Hessel EM.

J Pharmacol Exp Ther. 2019 Jun;369(3):337-344. doi: 10.1124/jpet.118.255109. Epub 2019 Mar 18.

PMID:
30886125
6.

Use of autologous 99mTechnetium-labelled neutrophils to quantify lung neutrophil clearance in COPD.

Tregay N, Begg M, Cahn A, Farahi N, Povey K, Madhavan S, Simmonds R, Gillett D, Solanki C, Wong A, Maison J, Lennon M, Bradley G, Jarvis E, de Groot M, Wilson F, Babar J, Peters AM, Hessel EM, Chilvers ER.

Thorax. 2019 Jul;74(7):659-666. doi: 10.1136/thoraxjnl-2018-212509. Epub 2019 Jan 23.

7.

A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.

Khindri S, Cahn A, Begg M, Montembault M, Leemereise C, Cui Y, Hogg A, Wajdner H, Yang S, Robertson J, Hamblin JN, Ludwig-Sengpiel A, Kornmann O, Hessel EM.

J Pharmacol Exp Ther. 2018 Dec;367(3):405-413. doi: 10.1124/jpet.118.249516. Epub 2018 Sep 14.

PMID:
30217958
8.

PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner.

Stark AK, Chandra A, Chakraborty K, Alam R, Carbonaro V, Clark J, Sriskantharajah S, Bradley G, Richter AG, Banham-Hall E, Clatworthy MR, Nejentsev S, Hamblin JN, Hessel EM, Condliffe AM, Okkenhaug K.

Nat Commun. 2018 Aug 9;9(1):3174. doi: 10.1038/s41467-018-05674-8.

9.

Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.

Wilson R, Jarvis E, Montembault M, Hamblin JN, Hessel EM, Cahn A.

Clin Ther. 2018 Aug;40(8):1410-1417. doi: 10.1016/j.clinthera.2018.06.011. Epub 2018 Jul 25.

PMID:
30055824
10.

The effects of repeated Toll-like receptors 2 and 4 stimulation in COPD alveolar macrophages.

Lea SR, Reynolds SL, Kaur M, Simpson KD, Hall SR, Hessel EM, Singh D.

Int J Chron Obstruct Pulmon Dis. 2018 Mar 2;13:771-780. doi: 10.2147/COPD.S97071. eCollection 2018.

11.

First-in-Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well-Tolerated.

Jackson S, Candia AF, Delaney S, Floettmann S, Wong C, Campbell JD, Kell S, Lum J, Hessel EM, Traquina P, McHale M, Robinson I, Bell J, Fuhr R, Keeling D, Coffman RL.

Clin Pharmacol Ther. 2018 Aug;104(2):335-345. doi: 10.1002/cpt.938. Epub 2017 Dec 6.

PMID:
29134633
12.

Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.

Cahn A, Hamblin JN, Begg M, Wilson R, Dunsire L, Sriskantharajah S, Montembault M, Leemereise CN, Galinanes-Garcia L, Watz H, Kirsten AM, Fuhr R, Hessel EM.

Pulm Pharmacol Ther. 2017 Oct;46:69-77. doi: 10.1016/j.pupt.2017.08.008. Epub 2017 Aug 17.

13.

Ampicillin resistance in Haemophilus influenzae from COPD patients in the UK.

Maddi S, Kolsum U, Jackson S, Barraclough R, Maschera B, Simpson KD, Pascal TG, Durviaux S, Hessel EM, Singh D.

Int J Chron Obstruct Pulmon Dis. 2017 May 22;12:1507-1518. doi: 10.2147/COPD.S135338. eCollection 2017.

14.

An investigation of the anti-inflammatory effects and a potential biomarker of PI3Kδ inhibition in COPD T cells.

Khan A, Southworth T, Worsley S, Sriskantharajah S, Amour A, Hessel EM, Singh D.

Clin Exp Pharmacol Physiol. 2017 Sep;44(9):932-940. doi: 10.1111/1440-1681.12784.

PMID:
28508433
15.

Altered fatty acid metabolism and reduced stearoyl-coenzyme a desaturase activity in asthma.

Rodriguez-Perez N, Schiavi E, Frei R, Ferstl R, Wawrzyniak P, Smolinska S, Sokolowska M, Sievi NA, Kohler M, Schmid-Grendelmeier P, Michalovich D, Simpson KD, Hessel EM, Jutel M, Martin-Fontecha M, Palomares O, Akdis CA, O'Mahony L.

Allergy. 2017 Nov;72(11):1744-1752. doi: 10.1111/all.13180. Epub 2017 May 10.

16.

Membrane nanoclusters of FcγRI segregate from inhibitory SIRPα upon activation of human macrophages.

Lopes FB, Bálint Š, Valvo S, Felce JH, Hessel EM, Dustin ML, Davis DM.

J Cell Biol. 2017 Apr 3;216(4):1123-1141. doi: 10.1083/jcb.201608094. Epub 2017 Mar 13.

17.

Histamine-secreting microbes are increased in the gut of adult asthma patients.

Barcik W, Pugin B, Westermann P, Perez NR, Ferstl R, Wawrzyniak M, Smolinska S, Jutel M, Hessel EM, Michalovich D, Akdis CA, Frei R, O'Mahony L.

J Allergy Clin Immunol. 2016 Nov;138(5):1491-1494.e7. doi: 10.1016/j.jaci.2016.05.049. Epub 2016 Jul 27. No abstract available.

PMID:
27576125
18.

IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment.

Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, Hartmann R, Wack A.

EMBO Mol Med. 2016 Sep 1;8(9):1099-112. doi: 10.15252/emmm.201606413. Print 2016 Sep.

19.
20.

Acute Respiratory Distress Syndrome Neutrophils Have a Distinct Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition.

Juss JK, House D, Amour A, Begg M, Herre J, Storisteanu DM, Hoenderdos K, Bradley G, Lennon M, Summers C, Hessel EM, Condliffe A, Chilvers ER.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):961-973.

21.

The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils.

Gupta V, Khan A, Higham A, Lemon J, Sriskantharajah S, Amour A, Hessel EM, Southworth T, Singh D.

Int Immunopharmacol. 2016 Jun;35:155-162. doi: 10.1016/j.intimp.2016.03.027. Epub 2016 Apr 16.

PMID:
27049289
22.

Genome-wide transcription profiling in neutrophils in acute respiratory distress syndrome.

Juss J, Herre J, Begg M, Bradley G, Lennon M, Amour A, House D, Hessel EM, Summers C, Condliffe AM, Chilvers ER.

Lancet. 2015 Feb 26;385 Suppl 1:S55. doi: 10.1016/S0140-6736(15)60370-1.

PMID:
26312877
23.

PI3K inhibitors in inflammation, autoimmunity and cancer.

Stark AK, Sriskantharajah S, Hessel EM, Okkenhaug K.

Curr Opin Pharmacol. 2015 Aug;23:82-91. doi: 10.1016/j.coph.2015.05.017. Epub 2015 Jun 18. Review.

24.

A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice.

Campbell JD, Kell SA, Kozy HM, Lum JA, Sweetwood R, Chu M, Cunningham CR, Salamon H, Lloyd CM, Coffman RL, Hessel EM.

Thorax. 2014 Jun;69(6):565-573. doi: 10.1136/thoraxjnl-2013-204605. Epub 2014 Jan 24.

25.

Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases.

Sriskantharajah S, Hamblin N, Worsley S, Calver AR, Hessel EM, Amour A.

Ann N Y Acad Sci. 2013 Mar;1280:35-9. doi: 10.1111/nyas.12039. Review.

PMID:
23551101
26.

Functions of T cells in asthma: more than just T(H)2 cells.

Lloyd CM, Hessel EM.

Nat Rev Immunol. 2010 Dec;10(12):838-48. doi: 10.1038/nri2870. Epub 2010 Nov 9. Review.

27.

Allergen-specific T cell responses to immunotherapy monitored by CD154 and intracellular cytokine expression.

Campbell JD, Buchmann P, Kesting S, Cunningham CR, Coffman RL, Hessel EM.

Clin Exp Allergy. 2010 Jul;40(7):1025-35. doi: 10.1111/j.1365-2222.2010.03505.x. Epub 2010 Apr 13.

PMID:
20412135
28.

CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans.

Campbell JD, Cho Y, Foster ML, Kanzler H, Kachura MA, Lum JA, Ratcliffe MJ, Sathe A, Leishman AJ, Bahl A, McHale M, Coffman RL, Hessel EM.

J Clin Invest. 2009 Sep;119(9):2564-76. doi: 10.1172/JCI38294. Epub 2009 Aug 10.

29.

Biomarkers measuring the activity of Toll-like receptor ligands in clinical development programs.

Sims P, Coffman RL, Hessel EM.

Methods Mol Biol. 2009;517:415-40. doi: 10.1007/978-1-59745-541-1_25.

PMID:
19378019
30.

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.

Kanzler H, Barrat FJ, Hessel EM, Coffman RL.

Nat Med. 2007 May;13(5):552-9. Review.

PMID:
17479101
31.

Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses.

Gauvreau GM, Hessel EM, Boulet LP, Coffman RL, O'Byrne PM.

Am J Respir Crit Care Med. 2006 Jul 1;174(1):15-20. Epub 2006 Mar 30.

PMID:
16574937
32.

Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction.

Hessel EM, Chu M, Lizcano JO, Chang B, Herman N, Kell SA, Wills-Karp M, Coffman RL.

J Exp Med. 2005 Dec 5;202(11):1563-73. Epub 2005 Nov 28.

33.

Nonhuman primate models of asthma.

Coffman RL, Hessel EM.

J Exp Med. 2005 Jun 20;201(12):1875-9.

34.

Superior activity of the type C class of ISS in vitro and in vivo across multiple species.

Marshall JD, Fearon KL, Higgins D, Hessel EM, Kanzler H, Abbate C, Yee P, Gregorio J, Cruz TD, Lizcano JO, Zolotorev A, McClure HM, Brasky KM, Murthy KK, Coffman RL, Nest GV.

DNA Cell Biol. 2005 Feb;24(2):63-72.

PMID:
15699627
35.

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS.

Blood. 2005 Jan 15;105(2):489-95. Epub 2004 Sep 9.

PMID:
15358617
36.

Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells.

Marshall JD, Hessel EM, Gregorio J, Abbate C, Yee P, Chu M, Van Nest G, Coffman RL, Fearon KL.

Nucleic Acids Res. 2003 Sep 1;31(17):5122-33.

37.

A restricted subset of dendritic cells captures airborne antigens and remains able to activate specific T cells long after antigen exposure.

Julia V, Hessel EM, Malherbe L, Glaichenhaus N, O'Garra A, Coffman RL.

Immunity. 2002 Feb;16(2):271-83.

38.

Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, Körner H, Scheerens H, Hessel EM, Cyster JG, McEvoy LM, Sedgwick JD.

Immunity. 2001 Oct;15(4):533-43.

39.

Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen.

Hellings PW, Hessel EM, Van Den Oord JJ, Kasran A, Van Hecke P, Ceuppens JL.

Clin Exp Allergy. 2001 May;31(5):782-90.

PMID:
11422139
40.

Airway epithelial Fas ligand expression: potential role in modulating bronchial inflammation.

Gochuico BR, Miranda KM, Hessel EM, De Bie JJ, Van Oosterhout AJ, Cruikshank WW, Fine A.

Am J Physiol. 1998 Mar;274(3):L444-9. doi: 10.1152/ajplung.1998.274.3.L444.

PMID:
9530181
41.

Involvement of IL-16 in the induction of airway hyper-responsiveness and up-regulation of IgE in a murine model of allergic asthma.

Hessel EM, Cruikshank WW, Van Ark I, De Bie JJ, Van Esch B, Hofman G, Nijkamp FP, Center DM, Van Oosterhout AJ.

J Immunol. 1998 Mar 15;160(6):2998-3005.

42.

Development of airway hyperresponsiveness is dependent on interferon-gamma and independent of eosinophil infiltration.

Hessel EM, Van Oosterhout AJ, Van Ark I, Van Esch B, Hofman G, Van Loveren H, Savelkoul HF, Nijkamp FP.

Am J Respir Cell Mol Biol. 1997 Mar;16(3):325-34.

PMID:
9070618
43.

Effect of dexamethasone and endogenous corticosterone on airway hyperresponsiveness and eosinophilia in the mouse.

De Bie JJ, Hessel EM, Van Ark I, Van Esch B, Hofman G, Nijkamp FP, Van Oosterhout AJ.

Br J Pharmacol. 1996 Dec;119(7):1484-90.

44.

Lung inflammation and epithelial changes in a murine model of atopic asthma.

Blyth DI, Pedrick MS, Savage TJ, Hessel EM, Fattah D.

Am J Respir Cell Mol Biol. 1996 May;14(5):425-38.

PMID:
8624247
45.

Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice.

Hessel EM, Van Oosterhout AJ, Hofstra CL, De Bie JJ, Garssen J, Van Loveren H, Verheyen AK, Savelkoul HF, Nijkamp FP.

Eur J Pharmacol. 1995 Dec 7;293(4):401-12.

PMID:
8748694
46.

Repeated measurement of respiratory function and bronchoconstriction in unanesthetized mice.

Hessel EM, Zwart A, Oostveen E, Van Oosterhout AJ, Blyth DI, Nijkamp FP.

J Appl Physiol (1985). 1995 Nov;79(5):1711-6.

PMID:
8594033
47.

Minimal immunological changes in structurally malformed rats after prenatal exposure to cyclophosphamide.

Hessel EM, Verhoef A, van Loveren H, Piersma AH.

Toxicology. 1994 Sep 6;92(1-3):287-99.

PMID:
7940567

Supplemental Content

Loading ...
Support Center